In a significant portfolio shift, Farallon Capital Management fully exited its position in Dianthus Therapeutics (DNTH), selling all 836,000 of its shares. The stake was previously valued at $70.16 million and represented about 0.40% of the hedge fund's reported portfolio.
This trade was disclosed in a quarterly 13F filing with the SEC on August 14, 2026, which details the firm's holdings as of June 30, 2026. The filing's delay means the actual sale occurred at some point during the second quarter. During that period, Dianthus initiated a Phase 3 trial for its drug claseprubart in June, but also saw its stock fall after a competitor, Sanofi, halted a trial for a similar therapy.